scholarly journals P221Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania

2014 ◽  
Vol 103 (suppl 1) ◽  
pp. S39.2-S39 ◽  
Author(s):  
L Mazilu ◽  
I R Parepa ◽  
A I Suceveanu ◽  
A Suceveanu ◽  
R Baz ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Secondary Prevention ◽  
Prospective Study ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 901
Author(s):  
Katja Perdan-Pirkmajer ◽  
Polona Žigon ◽  
Anja Boc ◽  
Eva Podovšovnik ◽  
Saša Čučnik ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Prospective Study ◽  
Anticoagulant Therapy ◽  
Predictive Value ◽  
Anticoagulation Therapy ◽  
Time Frame ◽  
Vein Thrombosis ◽  
Therapeutic Decisions ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

Antiphospholipid syndrome (APS) is an important cause of deep vein thrombosis (DVT). According to current APS classification criteria, APS cannot be confirmed until 24 weeks after DVT. This time frame results in frequent discontinuation of anticoagulant treatment before APS is diagnosed. Therefore, the aim of our study was to evaluate the potential predictive value of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) before discontinuation of anticoagulation therapy. Patients with newly diagnosed DVT were included into a 24-month prospective study. All patients received anticoagulant therapy. aCL and anti-β2GPI were determined at inclusion and every four weeks for the first 24 weeks and then one and two years after inclusion. APS was confirmed in 24/221 (10.9%) patients. At the time of acute DVT 20/24 (83.3%), APS patients had positive aCL and/or anti-β2GPI. Two patients had low aCL levels and two were negative at the time of acute DVT but later met APS criteria due to lupus anticoagulant (LA). Our data indicate that negative aCL and/or anti-β2GPI at the time of acute DVT make further aPL testing unnecessary; however, LA should be determined after discontinuation of anticoagulant therapy. Positive aCL and/or anti-β2GPI at the time of acute DVT have a strong positive predictive value for APS and may support therapeutic decisions.

A Prospective Study of Streptokinase and Heparin in the Treatment of Deep Vein Thrombosis

2009 ◽  
Vol 203 (1-6) ◽  
pp. 457-463 ◽  
Author(s):  
H. Arnesen ◽  
A. Heilo ◽  
E. Jakobsen ◽  
B. Ly ◽  
E. Skaga
Keyword(s):  
Deep Vein Thrombosis ◽  
Prospective Study ◽  
Vein Thrombosis ◽  
A Prospective Study ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document